The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life
Murine and chimeric RFB4 (anti-human CD22) monoclonal antibodies (MAbs) with mutations in their Fc portions were conjugated to recombinant ricin toxin A chain to generate immunotoxins. The resulting immunotoxins (ITs) constructed with chimeric RFB4 MAbs were designed to have longer or shorter half-l...
Gespeichert in:
| Veröffentlicht in: | International immunopharmacology 2005-07, Vol.5 (7), p.1279-1290 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1290 |
|---|---|
| container_issue | 7 |
| container_start_page | 1279 |
| container_title | International immunopharmacology |
| container_volume | 5 |
| creator | Pop, Laurentiu M. Liu, Xiaoyun Ghetie, Victor Vitetta, Ellen S. |
| description | Murine and chimeric RFB4 (anti-human CD22) monoclonal antibodies (MAbs) with mutations in their Fc portions were conjugated to recombinant ricin toxin A chain to generate immunotoxins. The resulting immunotoxins (ITs) constructed with chimeric RFB4 MAbs were designed to have longer or shorter half-lives but similar binding and cytotoxic properties. These ITs can now be evaluated in vivo for improved therapeutic indices. The characteristics of these ITs are the subject of this report. |
| doi_str_mv | 10.1016/j.intimp.2005.03.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17453835</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576905000950</els_id><sourcerecordid>17453835</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-818de99540137d2edf5ad2c6505b4809cd076dc462a63687887e0f7aa847200b3</originalsourceid><addsrcrecordid>eNp9kEtv1DAURiMEog_4Bwh5Q3dJ7cSPZIOEplCQKrEpa8tj3zR3lNiD7QD99_V0RuqOla-scx_fqaoPjDaMMnm9a9BnXPZNS6loaNdQ1r2qzlmv-popKl6XWkhVCyWHs-oipR2l5Z-zt9UZEwPjXdeeV4_3E5AH8BBNxuBJGAkuy-pDDv_QJ7Im9A_ETrhAREtMWVlvbtr2udoGh5CIDT4b9AdwWfPznET-TmgnYuYMkeQJMJIEcV3IZOaxnnGEd9Wb0cwJ3p_ey-rXt6_3m-_13c_bH5svd7XlLct1z3oHwyB4iadcC24UxrVWCiq2vKeDdVRJZ7lsjexkCd8roKMypueqmNl2l9XVce4-ht8rpKwXTBbm2XgIa9JMcdH1nSggP4I2hpQijHofcTHxUTOqD8r1Th-V64NyTTtdbiptH0_z1-0C7qXp5LgAn06ASbakj8ZbTC-c7BmnrSzc5yMHxcYfhKiTRfAWHEawWbuA_7_kCeC8onE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17453835</pqid></control><display><type>article</type><title>The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Pop, Laurentiu M. ; Liu, Xiaoyun ; Ghetie, Victor ; Vitetta, Ellen S.</creator><creatorcontrib>Pop, Laurentiu M. ; Liu, Xiaoyun ; Ghetie, Victor ; Vitetta, Ellen S.</creatorcontrib><description>Murine and chimeric RFB4 (anti-human CD22) monoclonal antibodies (MAbs) with mutations in their Fc portions were conjugated to recombinant ricin toxin A chain to generate immunotoxins. The resulting immunotoxins (ITs) constructed with chimeric RFB4 MAbs were designed to have longer or shorter half-lives but similar binding and cytotoxic properties. These ITs can now be evaluated in vivo for improved therapeutic indices. The characteristics of these ITs are the subject of this report.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2005.03.013</identifier><identifier>PMID: 15914332</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Animals ; Anti-CD22 ; Antibodies, Monoclonal - pharmacokinetics ; Antigens, CD - immunology ; Antigens, Differentiation, B-Lymphocyte - immunology ; Biological and medical sciences ; Cell Adhesion Molecules - immunology ; Cell Line ; Fc mutations ; FcRn ; Female ; Half-Life ; Humans ; Immunotoxins - pharmacokinetics ; Immunotoxins - pharmacology ; Lectins - immunology ; Medical sciences ; Mice ; Mutation ; Pharmacology. Drug treatments ; Ricin - pharmacokinetics ; Ricin A chain ; Sialic Acid Binding Ig-like Lectin 2 ; U937 Cells</subject><ispartof>International immunopharmacology, 2005-07, Vol.5 (7), p.1279-1290</ispartof><rights>2005 Elsevier B.V.</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-818de99540137d2edf5ad2c6505b4809cd076dc462a63687887e0f7aa847200b3</citedby><cites>FETCH-LOGICAL-c421t-818de99540137d2edf5ad2c6505b4809cd076dc462a63687887e0f7aa847200b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2005.03.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16814026$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15914332$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pop, Laurentiu M.</creatorcontrib><creatorcontrib>Liu, Xiaoyun</creatorcontrib><creatorcontrib>Ghetie, Victor</creatorcontrib><creatorcontrib>Vitetta, Ellen S.</creatorcontrib><title>The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>Murine and chimeric RFB4 (anti-human CD22) monoclonal antibodies (MAbs) with mutations in their Fc portions were conjugated to recombinant ricin toxin A chain to generate immunotoxins. The resulting immunotoxins (ITs) constructed with chimeric RFB4 MAbs were designed to have longer or shorter half-lives but similar binding and cytotoxic properties. These ITs can now be evaluated in vivo for improved therapeutic indices. The characteristics of these ITs are the subject of this report.</description><subject>Animals</subject><subject>Anti-CD22</subject><subject>Antibodies, Monoclonal - pharmacokinetics</subject><subject>Antigens, CD - immunology</subject><subject>Antigens, Differentiation, B-Lymphocyte - immunology</subject><subject>Biological and medical sciences</subject><subject>Cell Adhesion Molecules - immunology</subject><subject>Cell Line</subject><subject>Fc mutations</subject><subject>FcRn</subject><subject>Female</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Immunotoxins - pharmacokinetics</subject><subject>Immunotoxins - pharmacology</subject><subject>Lectins - immunology</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mutation</subject><subject>Pharmacology. Drug treatments</subject><subject>Ricin - pharmacokinetics</subject><subject>Ricin A chain</subject><subject>Sialic Acid Binding Ig-like Lectin 2</subject><subject>U937 Cells</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtv1DAURiMEog_4Bwh5Q3dJ7cSPZIOEplCQKrEpa8tj3zR3lNiD7QD99_V0RuqOla-scx_fqaoPjDaMMnm9a9BnXPZNS6loaNdQ1r2qzlmv-popKl6XWkhVCyWHs-oipR2l5Z-zt9UZEwPjXdeeV4_3E5AH8BBNxuBJGAkuy-pDDv_QJ7Im9A_ETrhAREtMWVlvbtr2udoGh5CIDT4b9AdwWfPznET-TmgnYuYMkeQJMJIEcV3IZOaxnnGEd9Wb0cwJ3p_ey-rXt6_3m-_13c_bH5svd7XlLct1z3oHwyB4iadcC24UxrVWCiq2vKeDdVRJZ7lsjexkCd8roKMypueqmNl2l9XVce4-ht8rpKwXTBbm2XgIa9JMcdH1nSggP4I2hpQijHofcTHxUTOqD8r1Th-V64NyTTtdbiptH0_z1-0C7qXp5LgAn06ASbakj8ZbTC-c7BmnrSzc5yMHxcYfhKiTRfAWHEawWbuA_7_kCeC8onE</recordid><startdate>20050701</startdate><enddate>20050701</enddate><creator>Pop, Laurentiu M.</creator><creator>Liu, Xiaoyun</creator><creator>Ghetie, Victor</creator><creator>Vitetta, Ellen S.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>20050701</creationdate><title>The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life</title><author>Pop, Laurentiu M. ; Liu, Xiaoyun ; Ghetie, Victor ; Vitetta, Ellen S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-818de99540137d2edf5ad2c6505b4809cd076dc462a63687887e0f7aa847200b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Animals</topic><topic>Anti-CD22</topic><topic>Antibodies, Monoclonal - pharmacokinetics</topic><topic>Antigens, CD - immunology</topic><topic>Antigens, Differentiation, B-Lymphocyte - immunology</topic><topic>Biological and medical sciences</topic><topic>Cell Adhesion Molecules - immunology</topic><topic>Cell Line</topic><topic>Fc mutations</topic><topic>FcRn</topic><topic>Female</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Immunotoxins - pharmacokinetics</topic><topic>Immunotoxins - pharmacology</topic><topic>Lectins - immunology</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mutation</topic><topic>Pharmacology. Drug treatments</topic><topic>Ricin - pharmacokinetics</topic><topic>Ricin A chain</topic><topic>Sialic Acid Binding Ig-like Lectin 2</topic><topic>U937 Cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pop, Laurentiu M.</creatorcontrib><creatorcontrib>Liu, Xiaoyun</creatorcontrib><creatorcontrib>Ghetie, Victor</creatorcontrib><creatorcontrib>Vitetta, Ellen S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pop, Laurentiu M.</au><au>Liu, Xiaoyun</au><au>Ghetie, Victor</au><au>Vitetta, Ellen S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2005-07-01</date><risdate>2005</risdate><volume>5</volume><issue>7</issue><spage>1279</spage><epage>1290</epage><pages>1279-1290</pages><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>Murine and chimeric RFB4 (anti-human CD22) monoclonal antibodies (MAbs) with mutations in their Fc portions were conjugated to recombinant ricin toxin A chain to generate immunotoxins. The resulting immunotoxins (ITs) constructed with chimeric RFB4 MAbs were designed to have longer or shorter half-lives but similar binding and cytotoxic properties. These ITs can now be evaluated in vivo for improved therapeutic indices. The characteristics of these ITs are the subject of this report.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>15914332</pmid><doi>10.1016/j.intimp.2005.03.013</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1567-5769 |
| ispartof | International immunopharmacology, 2005-07, Vol.5 (7), p.1279-1290 |
| issn | 1567-5769 1878-1705 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17453835 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Anti-CD22 Antibodies, Monoclonal - pharmacokinetics Antigens, CD - immunology Antigens, Differentiation, B-Lymphocyte - immunology Biological and medical sciences Cell Adhesion Molecules - immunology Cell Line Fc mutations FcRn Female Half-Life Humans Immunotoxins - pharmacokinetics Immunotoxins - pharmacology Lectins - immunology Medical sciences Mice Mutation Pharmacology. Drug treatments Ricin - pharmacokinetics Ricin A chain Sialic Acid Binding Ig-like Lectin 2 U937 Cells |
| title | The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T04%3A40%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20generation%20of%20immunotoxins%20using%20chimeric%20anti-CD22%20antibodies%20containing%20mutations%20which%20alter%20their%20serum%20half-life&rft.jtitle=International%20immunopharmacology&rft.au=Pop,%20Laurentiu%20M.&rft.date=2005-07-01&rft.volume=5&rft.issue=7&rft.spage=1279&rft.epage=1290&rft.pages=1279-1290&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2005.03.013&rft_dat=%3Cproquest_cross%3E17453835%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17453835&rft_id=info:pmid/15914332&rft_els_id=S1567576905000950&rfr_iscdi=true |